Endoscopic submucosal dissection for rectal neuroendocrine tumours: A multicentric retrospective study.

Introduction: Endoscopic Submucosal Dissection (ESD) has been reported as a feasible and effective treatment for Rectal Neuroendocrine Tumours (R-NETs). However, most of the experience on the topic comes from retrospective tertiary centre from Eastern Asia. Data on ESD for R-NETs in Western centres are lacking.
Materials and Methods: This is a retrospective study, including patients who underwent endoscopic resection of R-NETS by ESD between 2015 and 2020 in Western Centres. Important clinical variables such as demographic, size of R-NETs, histological type, presence of lymphovascular invasion or distant metastasis, completeness of the endoscopic resection, recurrence, and procedure related complications were recorded.
Results: 40 ESD procedure on R-NETs from 39 patients from 8 centres were included. Mean R-NETs size was 10.3 mm (SD 4.01). Endoscopic en-bloc resection was achieved in 39/40 ESD (97.5 %), R0 margin resection was obtained in 87.5 % (35/40) of the procedures, one patient was referred to surgery for lymphovascular invasion, two procedures (5 %) reported significant episodes of bleeding, whereas a perforation occurred in one case (1/40, 2.5 %) managed endoscopically. Recurrence occurred in 1 patient (2.5 %).
Conclusion: ESD is an effective and safe treatment for R-NETs in western centres.
Competing Interests: Conflict of interest The authors declare the following conflict of interest: AR: no disclosures. EJD: educational grants in support of conference organization, and honoraria, from Fujifilm, Pentax, and Olympus, and honoraria from Ambu. RC: no disclosures. NL: no disclosures. DC: no disclosures. AB: no disclosures. DM: no disclosures. MP: consultancy and training for Olympus, Pentax, Cook, and Norgine. JR: consultancy and training for Olympus, Pentax, Cook, and Norgine. JSA: faculty member in advanced endoscopy courses by Olympus. MM: no disclosure. FRZ: consultant for Erbe España Soluciones Médicas. FB: consulting fees for OLYMPUS. PPN: no disclosures. MDR: no disclosures. EA: no disclosures. MT: no disclosures. CS: consultant for Medtronic, Norgine, and AlfaSigma, grants from Olympus and Pentax. AL: Boston Scientific, Research grant; Medtronic, research grant; Erbe, speaker's fees. MC: no disclosures. CT: no disclosures. AM: Personal payments/honoraria/fees: Olympus, GI supply, Boston Scientific, Fujifilm.
(Copyright © 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)